Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mike R. Stratford
Observed names:
M R Stratford,
M. R. Stratford,
M. Stratford,
Mike Stratford
Institutions:
Churchill Hospital,
Cancer Research UK,
John Radcliffe Hospital,
University of Oxford,
CRUK/MRC Oxford Institute for Radiation Oncology
Observed institutions:
Mount Vernon Hospital,
Churchill Hospital,
Cancer Research UK,
John Radcliffe Hospital,
University of Manchester,
University of Oxford,
CRUK/MRC Oxford Institute for Radiation Oncology,
Mount Vernon Cancer Centre,
The Christie NHS Foundation Trust
show all 9
OpenAlex ID:
A5113853213
Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
2010
·
Isabel M. Pires
, Zuzana Bencokova
, et al.
·
Cancer Research
·
234
PDF
Modelling a Research Portfolio Using AHP: A Group Decision Process
1986
·
Geoff Lockett
, Barrie Hetherington
, et al.
·
R and D Management
·
93
A decision support system using judgmental modeling: a case of R&D in the pharmaceutical industry
1991
·
G. Islei
, G. Lockett
, et al.
·
IEEE Transactions on Engineering Management
·
51
Modeling Strategic Decision Making and Performance Measurements at ICI Pharmaceuticals
1991
·
Gerd Islei
, Geoff Lockett
, et al.
·
INFORMS Journal on Applied Analytics
·
42
Ranking of research projects: Experiments with two methods
1987
·
Geoff Lockett
, Mike Stratford
·
Omega
·
37
Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours
2007
·
D. M. Patterson
, P. Ross
, et al.
·
Journal of Clinical Oncology
·
12
Resource management and strategic decision making in industrial R&D departments:
1990
·
Gerd Islei
, Geoff Lockett
, et al.
·
Engineering Costs and Production Economics
·
10
Phase I evaluation of vascular disrupting agent OXi4503
2008
·
D. M. Patterson
, N. Charnley
, et al.
·
Journal of Clinical Oncology
·
9
Modelling a research portfolio using AHP — a group decision process
1987
·
Geoff Lockett
, Mike Stratford
, et al.
·
Mathematical Modelling
·
8
Nitric oxide involvement in the toxicity of hydroxyguanidine in leukaemia HL60 cells.
1996
·
S A Everett
, K A Smith
, et al.
·
Europe PMC (PubMed Central)
·
5
Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors.
2010
·
M. Zweifel
, D. M. Patterson
, et al.
·
Journal of Clinical Oncology
·
4
A phase I/II trial of radioimmunotherapy with 131Iodine labelled A5B7 anti-CEA antibody (131I-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas
2008
·
A. M. Gaya
, J. Violet
, et al.
·
Journal of Clinical Oncology
·
4
Ranking, Monitoring and Control of Research Projects in the Pharmaceutical Industry
1989
·
Gerd Islei
, Barry Cox
, et al.
·
Lecture notes in economics and mathematical systems
·
2
A PET imaging study of the vascular disruptive agent OXi4503 to confirm in vivo mechanism of action in a phase I trial
2009
·
P. M. Price
, M. Asselin
, et al.
·
Journal of Clinical Oncology
·
1
Supplementary Figure Legends 1-5 from Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
2023
·
Isabel M. Pires
, Zuzana Bencokova
, et al.
Supplementary Figures 1-5 from Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
2023
·
Isabel M. Pires
, Zuzana Bencokova
, et al.
Data from Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
2023
·
Isabel M. Pires
, Zuzana Bencokova
, et al.
Interim results from a phase I trial of the vascular disrupting agent OXi4503
2007
·
Daniel Patterson
, Phillip Ross
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
18
Citation count:
512
H-index:
8
I10-index:
7
Year
Topic
Type